S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:FENC

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

$7.04
-0.04 (-0.56%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.81
$7.25
50-Day Range
$5.31
$7.08
52-Week Range
$3.37
$7.59
Volume
44,666 shs
Average Volume
38,369 shs
Market Capitalization
$183.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
70.3% Upside
$12.00 Price Target
Short Interest
Bearish
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Fennec Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

869th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

140th out of 175 stocks

FENC stock logo

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Stock Down 0.5 %

NASDAQ:FENC traded down $0.04 during trading hours on Thursday, reaching $7.05. 44,666 shares of the company were exchanged, compared to its average volume of 38,369. The company has a debt-to-equity ratio of 0.36, a quick ratio of 8.96 and a current ratio of 8.96. The stock's 50-day moving average is $6.17 and its 200-day moving average is $5.74. Fennec Pharmaceuticals has a twelve month low of $3.37 and a twelve month high of $7.59.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts expect that Fennec Pharmaceuticals will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on FENC shares. Craig Hallum reissued a "buy" rating and set a $14.00 price target on shares of Fennec Pharmaceuticals in a report on Monday. Wedbush restated an "outperform" rating on shares of Fennec Pharmaceuticals in a research report on Wednesday, April 27th.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

Fennec Resubmits Pedmark NDA To FDA
Fennec Pharmaceuticals GAAP EPS of -$0.18
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings
11/10/2021
Today
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+70.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-17,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$170,000.00
Book Value
$0.61 per share

Miscellaneous

Free Float
23,544,000
Market Cap
$183.64 million
Optionable
Optionable
Beta
0.09

Key Executives

  • Mr. Rostislav Raykov (Age 42)
    Pres, CEO & Director
  • Mr. Robert C. Andrade (Age 43)
    Chief Financial Officer
  • Mr. Mark Gowland
    Controller
  • Mr. Lei Fang
    Pres of Pharstat Inc
  • Ms. Anne McKay (Age 64)
    Regulatory Consultant













FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price forecast for 2022?

4 Wall Street analysts have issued 1 year price targets for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $10.00 to $14.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 74.4% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2022?

Fennec Pharmaceuticals' stock was trading at $4.40 on January 1st, 2022. Since then, FENC stock has increased by 56.4% and is now trading at $6.88.
View the best growth stocks for 2022 here
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (0.03%).
View institutional ownership trends
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $6.88.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $179.36 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.